i3collect today announced that its Paperless Chain of Custody Form (PCCF™), developed in partnership with Premier Biotech’s wholly-owned subsidiary, Desert Tox, a SAMHSA-certified laboratory, has received approval through the National Laboratory Certification Program (NLCP).
This milestone establishes the first commercially available fully paperless chain-of-custody solutions for regulated drug testing, allowing employers to move beyond traditional paper-based workflows while maintaining compliance requirements.
Regulated drug testing chain-of-custody processes have long relied on generating physical documentation at various stages of collection, laboratory processing, and review. The newly approved PCCF™ solution enables the collection process to be managed digitally, reducing collector errors and administrative complexity while supporting greater efficiency throughout the testing workflow.
“Partnering with i3collect to achieve NLCP approval for the first commercially available paperless CCF is a massive win for our laboratory, our safety-sensitive clients, and the entire industry,” said Matthew Michalik, CEO of Premier Biotech. “Legacy systems have kept drug testing anchored to paper for far too long. i3collect’s platform enabled our technical teams to move with remarkable speed. Together, we are setting a new industry benchmark—combining agile software with trusted laboratory excellence to deliver seamless and efficient, regulated drug testing results.”
The achievement reflects extensive collaboration between i3collect’s technology team and the laboratory professionals at Premier Biotech’s wholly-owned subsidiary, Desert Tox, to validate a paperless workflow within the rigorous requirements of regulated drug testing.
“For years, the industry has relied on ‘electronic lite’ solutions that still require paper behind the scenes,” said Myranda Roys, Senior Vice President of i3collect. “Our vision was to create a truly end-to-end digital platform that eliminates unnecessary paperwork, reduces errors, and simplifies compliance for collection sites, laboratories, and employers. Achieving this milestone with Desert Tox demonstrates what is possible when innovative software and laboratory expertise come together. We believe this is a major step forward for the industry, and we’re just getting started.”
The approved PCCF™ solution is designed to support collection sites, laboratories, employers, TPAs, and transportation industry stakeholders seeking to streamline drug testing operations while maintaining regulatory compliance.
About i3collect
i3collect develops technology solutions that modernize drug testing and occupational health workflows through intelligent digital platforms. By replacing manual processes with connected software solutions, i3collect helps improve efficiency, compliance, and user experience across the testing lifecycle. Learn more at www.i3collect.com.
About Desert Tox & Premier Biotech
Desert Tox is a high-complexity HHS-certified laboratory and wholly-owned subsidiary of Premier Biotech. Premier Biotech provides drug testing solutions, laboratory services, and diagnostic technologies supporting workplace, clinical, and criminal justice markets throughout North America. Learn more at www.premierbiotech.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20261112826986/en/
Media gallery
